ITM Isotope Technologies Munich SE

#FridayRecap: Thank you for the amazing feedback over the past few weeks! We are proud of the positive response to our recent funding announcement and the #leadership change coming in September. Your support here on LinkedIn and also at last month’s #SNMMI in Toronto have been incredibly encouraging. For any healthcare professionals who missed our SNMMI symposium, you can watch a recording here: https://lnkd.in/ePcxZGhr We also want to extend a special thank you to the media for your openness hearing our story. Your coverage of our industry helps to build awareness of #radiopharmaceutical therapy and the potential benefits it can potentially bring to patients worldwide. Today is another special day for us as we celebrate 20 years of ITM at our employee Town Hall and our annual summer party! 🎉

We are proud to announce that we have received the German #Top100 #InnovationAward! The TOP 100 Award is the only innovation competition in Germany that recognizes medium-sized companies for their excellence in #innovation management and success. Each company is evaluated on a scientific study with over 100 criteria in five categories and we are proud to have achieved the highest grade of A+ for our innovation strength. This award is a testament to the hard work and innovative spirit of our entire team. A huge thank you to everyone who contributed to this success. #Teamwork Andrea Schwarz-Dyminski, Head of Global Human Resources, and Sebastian Marx, Chief Business Officer, had the honor of receiving the award on behalf of ITM from science journalist Ranga Yogeshwar at the official ceremony in Weimar. Here are some highlights from the Innovationswettbewerb TOP 100 event:

Did you know that according to the Indiana University School of Medicine, only 60% of men get a routine annual check-up while 40% wait until something is seriously wrong before seeing a doctor? June is #MensHealthMonth. Let's raise awareness about men's #health issues and the importance of regular check-ups. Regular health screenings, especially for #prostatecancer, can prevent serious diseases and ensure early detection.  See below for more essential facts about this disease #prostatecancer. 👇

ITM was thrilled to host Gil Schaenzle as she Cycles the Canals to raise awareness of and funding for Neuroendocrine Cancer (NET) education, with support from The Healing NET Foundation. Gil is the proud mother of Anna Rose Schaenzle, a vibrant and courageous young woman who passed away from high-grade NET cancer in 2017, just after her 21st birthday. NETs are frequently misdiagnosed with common diseases, and can often take an average of five years to accurately diagnose. Therefore, every effort to raise awareness of NET cancers is important to improve research, diagnosis, and treatment for patients worldwide. We are honored that Gil made a stop on her journey at #ITMUSA headquarters in Princeton to speak about this easily overlooked disease with neuroendocrine specialist Eric Liu from Rocky Mountain Cancer Centers, Mia S. Tepper, MBA the Executive Director of #HealingNET, Munir Ghesani MD, FACNM, FACR, FSNMMI, Chief Medical Officer at United Theranostics and Michael Morris, one of the founding physicians of United Theranostics. Join us in cheering for Gil on her 1,000-mile ride from Ohio to Washington, DC. To learn more about her inspiring story click here: https://lnkd.in/gyy7e7Ab #NeuroendocrineCancer #diseaseawareness #LetsTalkAboutNETs

📣 Exciting Leadership Change at ITM! 📣 We are thrilled to announce a significant leadership change: Andrew Cavey will join ITM as our new CEO on September 1. Andrew’s impressive career spans clinical development, corporate strategy and commercial management across international biotech and #radiopharmaceutical companies including Bristol Myers Squibb (BMS) and Novartis. Our current CEO Steffen Schuster will transition to a new role on our Supervisory Board, where his strategic expertise will continue to guide and advise ITM. As a healthcare executive and physician, Andrew has a remarkable track record of leading successful radiopharmaceutical development at leading global #biotech and #pharma organizations. Together with ITM’s leadership team, he will drive the next stages of growth, advancing our targeted radiopharmaceutical pipeline and expanding our world-leading medical #radioisotope manufacturing capabilities. Welcome Andrew and we thank you Steffen for your immeasurable contributions to ITM over more than 12 years! For more information, see our announcement: https://lnkd.in/dxkPMUiA

Drug Target Review has published an interview with our CMO Danielle Meyrick, PhD, MD, as part of their "Women in STEM" series. 👩🔬💬 In this inspiring article, Dr. Meyrick shares insights from her journey and the pivotal role she plays in providing clinical #leadership to ITM's #radiopharmaceutical development platform. Read the full interview and draw from her impressions of the scientific field, her personal career experiences, and her belief in #NuclearMedicine: https://lnkd.in/dRzQfqtX

Our sincerest thanks to everyone who took the time to stop by and sign our 20th Anniversary card at #SNMMI24 to help raise money for the Dream Foundation. Together we were able to make a patient’s dream come true. #ITM #dreamfoundation #charity #grateful

Please join us this evening for the ITM Dinner Symposium “𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙉𝙚𝙚𝙙𝙨 𝘿𝙧𝙞𝙫𝙞𝙣𝙜 𝙍𝙖𝙙𝙞𝙤𝙥𝙝𝙖𝙧𝙢𝙖𝙘𝙚𝙪𝙩𝙞𝙘𝙖𝙡 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙖𝙣𝙙 𝙎𝙘𝙖𝙡𝙖𝙗𝙡𝙚 𝙎𝙤𝙡𝙪𝙩𝙞𝙤𝙣𝙨” at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. Our distinguished panel of speakers will provide valuable insights into the well-established clinical utility of beta-emitting Lu-177 therapies and the potential of alpha-emitting Ac-225 and Auger-emitting Tb-161. They will also examine ongoing research that supports the development of new radiopharmaceuticals and how a sustainable supply of isotopes is being established to address the rapidly growing demands of clinicians and researchers worldwide. 📅 June 9, 2024, at 6:30pm – 7:30pm To learn more about this exciting program visit https://lnkd.in/ePcxZGhr #ITM #theranostics #nuclearmedicine #radiopharmaceuticals #radioisotopes

Join the ITM Team in Booth #1317 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to celebrate 20 years of our shared dedication to improving clinical outcomes and quality of life for patients and help us make patients’ dreams come true! For everyone that stops by and signs our anniversary card, ITM will donate to the Dream Foundation in support of their mission of providing patients and their families the opportunity to fulfill their dreams. ITM is proud to partner with the Dream Foundation for our shared goal of improving the quality of life for patients. If you can’t stop by but wish to learn more about the Dream Foundation, please visit www.dreamfoundation.org. Thank you for your continued support over the past 20 years! We look forward to celebrating with you! #ITM #SNMMI24 #Radioisotopes #Radiopharmaceuticals #theranostics

Today we are pleased to announce a €188 million equity #investment led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne. This new capital will enable us to achieve our next major milestones on providing cancer patients with more effective targeted treatment to improve clinical outcomes and quality of life: 💡 Advancing and expanding our targeted #radiopharmaceutical pipeline 🔬 Preparing for the potential launch of our Phase III lead candidate, #ITM-11, as it nears clinical read-out 🏭 Expanding our manufacturing capabilities for alpha- and beta-emitting #radioisotopes, including Lutetium-177 and Actinium-225. Read the full announcement here: https://lnkd.in/d5pQvE_u